Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

First in-human trial of AMV564 for AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 842

Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA

Dr Westervelt speaks with ecancer at EHA 23 about pre-clinical and early clinical results of a CD3/33 bi-specific T cell engager (BiTE) to treat AML.

He outlines the data from early mouse models and human cell cultures which showed activity of the molecule, and the pharmacodynamics seen in this phase I trial.

Dr Westervelt describes the escalating doses of the trial, noting a single incidence of grade 2 cytokine release syndrome, and sets out near-term goals for further trial expansion and validation.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

20.11.18

no rating
Nurse course: education sharing

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation